Merck & Co., Inc.
↗Rahway, New Jersey, United States
Merck & Co., Inc. is an American multinational pharmaceutical company and one of the world's largest pharmaceutical manufacturers. Founded in 1891 by George Merck as a chemicals distributor in New York City, it expanded significantly following its 1953 merger with Philadelphia-based Sharp & Dohme, Inc., making it the largest U.S. drugmaker at the time. The company is ranked fourth among the largest biomedical companies by revenue globally. Merck operates as MSD (Merck Sharp & Dohme) in the United States and Canada, and conducts extensive research and development across multiple therapeutic areas including oncology, immunology, infectious diseases, vaccines, and cardiometabolic conditions. The company generates nearly half its revenue from its flagship immunotherapy drug Keytruda (pembrolizumab), with significant contributions from its vaccine portfolio including Gardasil and other prevention therapies.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology, Immunology, Vaccines, Infectious Diseases, Cardiometabolic
SIZE & FINANCIALS
Employees:10000+
Revenue:$64.17B
Founded:1891
Ownership:public
Status:operating
STOCK
Exchange:NYSE
Ticker:MRK
Market Cap:$262.91B
PIPELINE
Stage:Phase 1-Phase 3 and Commercial
Lead Drug Stage:Keytruda - Commercial (multiple approved indications)
Modalities:Small molecule, Monoclonal antibodies (mAb), Antibody-drug conjugates (ADC), mRNA vaccines, Peptide-drug conjugates (PDC), Targeted protein degraders, Covalent inhibitors, Cell therapy, T-cell engagers
Trial Phases:Phase 3: 20
FDA Approvals:70
CORPORATE STRUCTURE
Subsidiaries:Merck Animal Health, Merck Serono
Key Partnerships:Daiichi Sankyo - $4B collaboration for three DXd antibody-drug conjugate candidates, Abbisko Therapeutics - $85M option fee for tenosynovial giant cell tumor treatment, Caris - $1.4B biobuck deal for ADC pipeline expansion, Kelun-Biotech - ADC collaboration, Acceleron Pharma - Acquired for pulmonary hypertension expertise
COMPETITION
Position:Leader
Competitors:Pfizer, Johnson & Johnson, Roche, Novartis, Bristol-Myers Squibb, AbbVie, Eli Lilly, GlaxoSmithKline (GSK)
LEADERSHIP
Key Executives:
Robert M. Davis - Chairman, President & Chief Executive Officer
Caroline Litchfield - Executive Vice President & Chief Financial Officer
Betty D. Larson - Executive Vice President & Chief Human Resources Officer
Cristal N. Downing - Executive Vice President & Chief Communications & Public Affairs Officer
David M. Williams - Executive Vice President & Chief Information and Digital Officer
Joseph Romanelli - President, Human Health International
Li - President, Merck Research Laboratories
Scientific Founders:George Merck
Board Members:Robert M. Davis (CEO, Chairman), Douglas M. Baker, Jr., Pamela J. Craig, Thomas H. Glocer, Surendralal L. Karsanbhai (joined January 1, 2025), Risa J. Lavizzo-Mourey, M.D., Stephen L. Mayo, Ph.D., Paul B. Rothman, M.D., Patricia F. Russo, Christine E. Seidman, M.D., Inge G. Thulin, Kathy J. Warden
LINKS
Website:merck.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Merck & Co., Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.